Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors
Status:
Completed
Trial end date:
2016-07-28
Target enrollment:
Participant gender:
Summary
This phase I trial using the EffTox design will evaluate activity and safety of alisertib, an
Aurora A kinase inhibitor, when given in combination with the selective VEGFR inhibitor
pazopanib in patients with advanced, previously treated non-hematologic solid tumors.